Alnylam Pharmaceuticals (ALNY) Capital Expenditures (QoQ) (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) Capital Expenditures (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.46 Bn | 34.45 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.53% |
| Dec 31, 2025 | 459.42% |
| Sep 30, 2025 | -195.56% |
| Jun 30, 2025 | 59.34% |
| Mar 31, 2025 | -1.36% |
| Dec 31, 2024 | -62.30% |
| Sep 30, 2024 | 2,145.80% |
| Jun 30, 2024 | -152.59% |
| Mar 31, 2024 | 105.20% |
| Dec 31, 2023 | -352.15% |
| Sep 30, 2023 | 7.37% |
| Jun 30, 2023 | 14.60% |
| Mar 31, 2023 | -78.92% |
| Dec 31, 2022 | 337.42% |
| Sep 30, 2022 | -272.89% |
| Jun 30, 2022 | -10.10% |
| Mar 31, 2022 | 143.68% |
| Dec 31, 2021 | -256.88% |
| Sep 30, 2021 | 23.31% |
| Jun 30, 2021 | 189.96% |